Bio-outsourcing

Recipharm to offer new metal-based delivery tech

13-May-2013 By Gareth Macdonald

Melding metals to APIs could make drugs easier to deliver according to Sweden's Recipharm which partnered to add a new chemistry to its offering last week.

Fujifilm's Cell Banking Facilitates "Larger Slice" of Biologics Pie

23-Apr-2013 By Dan Stanton

Third-party manufacturers of biologics are seeing increased demand but more short term contracts, according to Fujifilm.

ATMI Adds New Single-Use Fill/Finish Tech in Deal with CMO D-Lab

18-Apr-2013 By Gareth Macdonald

ATMI has started selling a new cGMP-compliant fill finish platform in a continuation of its focus on what it says is the growing single-use tech market.

Catalent Gets ADC Tech and Enters Fast-Growing Niche Market

11-Apr-2013 By Dan Stanton

Catalent says it will focus on providing technology for the ADC and biologics market as it becomes the latest CMO to invest in the field.

Client Demand Pushes Early Phase Australian CRO to Expand to Large Molecules

10-Apr-2013 By Zachary Brennan

Early phase clinical trial provider CPR Pharma Services has expanded its bioanalytical offerings with a ligand-binding assay service for its clients developing large molecules such as biologics, monoclonal antibodies and biosimilars.

Lonza Reaffirms Commitment to Teva Biosimilars JV in Light of 'Inaccurate' Reports

03-Apr-2013 By Gareth Macdonald

Lonza has reiterated its commitment to its biosimilars JV with Teva after various news stories hinted the future of the partnership was in doubt.

WuXi Expands Antibody Discovery Partnership with Transgenic Animal Developer

07-Mar-2013 By Zachary Brennan

WuXi PharmaTech has expanded its partnership with Open Monoclonal Technology (OMT) to use its transgenic rats and mice in China and other Asian countries.

Biosimilars: Is the Market Getting Too Much Attention?

06-Mar-2013 By Zachary Brennan

As anticipation swells over how the biosimilar market will shape up in the US, some contract biologic manufacturing executives don’t seem to think the size of the market is worth all of the hype yet.

Dispatches from Informex

Biopharma CMO Market’s Recent Downturn Could be Short-Lived

25-Feb-2013 By Zachary Brennan

Biopharmaceutical CMOs have seen their business slowly shrink as companies seek less volume and smaller batches, but outsourcing is expected to increase over the next three years.

Quintiles Confirms 'Go Public' Speculation with IPO and Predicts Rosy Future for CROs

18-Feb-2013 By Gareth Macdonald

Quintiles painted a rosy picture of the CRO sector in its much anticipated IPO, predicting that biopharma R&D spending will increase and demand for outsourced research will grow.

FDA to Release Long-Awaited Guidance on CMO Agreements, Biosimilars in 2013

04-Feb-2013 By Zachary Brennan

Highly sought-after guidance on quality agreements for contract manufacturing organizations (CMOs) and biosimilar developers is expected in 2013, according to a list of future guidance documents released by the US Food and Drug Administration (FDA).

GenScript plays piper bringing transgenic rats to Asia

29-Jan-2013 By Dan Stanton

GenScript says the chance to expand into Asia is the drive for taking its drug delivery platform out on the road.

ADC Bio open to antibody drug conjugate collaborations and CMO takovers

21-Jan-2013 By Gareth Macdonald

ADC Biotechnology has secured funding to take its cost-cutting antibody drug conjugate (ADC) tech to market and says pharma demand will drive partnerships and maybe even attract CMO takeover bids.

Recipharm adds analytical capacity at Swedish plant

04-Dec-2012

Swedish CMO Recipharm has added capacity for analytical services and stability studies at its laboratory in Solna, Sweden

Restart of Singapore plant project unlikely to affect Lonza deal, says Novartis

12-Nov-2012 By Gareth Macdonald

Novartis says the decision to reactivate plans for a biotechnology plant in Singapore is unlikely to affect its deal with Lonza.

Fujifilm and Piramal team on ADC manufacturing

24-Oct-2012 By Gareth Macdonald

Fujifilm Diosynth Biotechnologies has partnered with Piramal Healthcare on development and manufacture of ADCs.

Cobra says timesaving cell line development tech will help it win customers

24-Aug-2012 By Gareth Macdonald

Cobra Biologics claims a new micro bioreactor technology it has adopted can cut three months off cell line development timelines and facilitate faster production scale-up.

DSM to continue Phama cuts beyond recent Percivia reorganisation

07-Aug-2012 By Gareth Macdonald

DSM will conduct further cost cutting at its Pharma business as part of a wider ‘profit improvement initiative’ that will see it cut 1,000 jobs over the next 18 months.

Parexel acknowledges new BioPharm unit's matchmaking potential

07-Aug-2012 By Gareth Macdonald

Parexel may be willing to act as a matchmaker for the small and midsized developers that work with its new BioPharm unit according to COO Mark Goldberg.

DSM's CMO biz wins second contract in two months

17-Jul-2012

DSM Pharmaceutical Products (DPP) has won its second biologics manufacturing contract in two months signing up Brazil’s Recepta Biopharma as a new customer.